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Abstract
Background: Recent genome-wide association studies have identified a number of common variants associated with
fasting glucose homeostasis and type 2 diabetes in populations of European origin. This is a replication study to examine
whether such associations are also observed in Chinese Hans.
Methods: We genotyped nine variants in or near MADD, ADRA2A, CRY2, GLIS3, PROX1, FADS1, C2CD4B, IGF1 and IRS1 in a
population-based cohort including 3,210 unrelated Chinese Hans from Beijing and Shanghai.
Results: We confirmed the associations of GLIS3-rs7034200 with fasting glucose (beta=0.07 mmol/l, P=0.03), beta cell
function (HOMA-B) (beta=23.03%, P=0.009), and type 2 diabetes (OR [95%CI] =1.27 [1.09–1.49], P=0.003) after
adjustment for age, sex, region and BMI. The association for type 2 diabetes remained significant after adjusting for other
diabetes related risk factors including family history of diabetes, lipid profile, medication information, hypertension and life
style factors, while further adjustment for HOMA-B abolished the association. The A-allele of CRY2-rs11605924 was
moderately associated with increased risk of combined IFG/type 2 diabetes (OR [95%CI] =1.15[1.01–1.30], P=0.04). SNPs in
or near MADD, ADRA2A, PROX1, FADS1, C2CD4B, IGF1, and IRS1 did not exhibit significant associations with type 2 diabetes
or related glycemic traits (P$0.10).
Conclusions: In conclusion, our results indicate the associations of GLIS3 locus with type 2 diabetes and impaired fasting
glucose in Chinese Hans, partially mediated through impaired beta-cell function. In addition, we also found modest
evidence for the association of CRY2-rs11605924 with combined IFG/type 2 diabetes.
Citation: Liu C, Li H, Qi L, Loos RJF, Qi Q, et al. (2011) Variants in GLIS3 and CRY2 Are Associated with Type 2 Diabetes and Impaired Fasting Glucose in Chinese
Hans. PLoS ONE 6(6): e21464. doi:10.1371/journal.pone.0021464
Editor: Sunil K. Ahuja, South Texas Veterans Health Care System, United States of America
Received October 18, 2010; Accepted June 2, 2011; Published June 29, 2011
Copyright:  2011 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was funded by the research grants from the Chief Scientist Program of Shanghai Institutes for Biological Sciences, Chinese Academy of
Sciences (SIBS2008006), the Major Projects of Knowledge Innovation Program (KSCX1-YW-02), the National Natural Science Foundation of China (30930081), and
National High Technology Research and Development Program (863 Program) (2009AA022704). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: lihx@sibs.ac.cn (HL); xlin@sibs.ac.cn(XL)
Introduction
Genome-wide association studies (GWAS) have achieved great
success in identifying common genetic variants associated with
type 2 diabetes. However, most of the diabetes-related genetic
variants identified by GWAS appear to influence insulin secretion
rather than insulin resistance [1]. Recently, a GWAS of type 2
diabetes identified a type 2 diabetes risk variant (rs2943641, near
IRS1) that was associated with insulin resistance and hyperinsu-
linemia in populations of European ancestry [2]. Remarkably,
previous candidate gene association studies also observed that
IRS1-rs1801278 (G972R, not in linkage disequilibrium with
rs2943641) was associated with whole body insulin resistance
[3,4], but generated inconsistent results and not associated with
type 2 diabetes [5]. More recently, a large genome-wide meta-
analysis of data from 21 GWAS in populations of European origin
identified a common variant near IGF1 associated with hyperin-
sulinemia and insulin resistance (HOMA-IR), and nine novel loci
(in or near ADCY5, MADD, ADRA2A, CRY2, FADS1, GLIS3,
PROX1, SLC2A2, C2CD4B) influencing fasting glucose [6]. The
associations of ADCY5 and PROX1 loci with type 2 diabetes also
reached genome-wide significance [6]. Each of these loci had a
small effect on fasting glucose (0.008 to 0.030 mmol/l per allele),
and in combination with the previously identified G6PC2,
MTNR1B, GCK, GCKR and DGKB-TMEM195 loci they explained
only 4% of the variation in fasting glucose [6]. A replication study
in the Danish population-based Inter99 cohort (5,722 non-diabetic
individuals) confirmed that the DGKB-TMEM195, ADRA2A,
GLIS3, C2CD4B and PROX1 loci were significantly associated
with reduced glucose-stimulated beta cell function [7]. More
recently, another study in a case-control sample of Chinese also
replicated the associations of DGKB, MADD, GLIS3, PROX1 and
IGF1 with type 2 diabetes and/or glycemic traits [8].
However, most of the previous studies were conducted in case-
control samples, and study in a general population has more
potential to provide insight into mechanisms by which genetic
variants contribute to type 2 diabetes. We therefore examined
whether these novel loci identified by recent GWAS studies are
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population-based cohort of 3,210 unrelated Han Chinese from
Beijing and Shanghai.
Methods
Study design
The study population for the present study consisted of 3,210
unrelated Chinese Hans (1,423 men and 1,787 women) aged 50–
70 years from the Study on Nutrition and Health of Aging
Population in China. The study design and protocol has been
described in detail previously [9]. Briefly, the study was
implemented simultaneously in both geographic locations from
March to June 2005. A multistage sampling method was used to
recruit the participants from Beijing and Shanghai. Two urban
districts and one rural district in both cities were chosen and the
eligible candidates listed in the residential registration record were
selected randomly. All participants attended a physical examina-
tion during which standard anthropometric measurements and
fasting blood samples were collected. Type 2 diabetes was defined
as fasting plasma glucose $7.0 mmol/l or previously diagnosed
diabetic and receiving glucose-lowering treatment (N=424: 37%
screen-detected, 63% previously diagnosed and receiving anti-
diabetic treatment) [10]. Normal fasting glucose (NFG) (N=1,908)
was defined as nondiabetic individuals having fasting glucose,
5.6 mmol/l, and impaired fasting glucose (IFG) (N=878, all were
screen-detected and treatment-naive) was defined as nondiabetic
individuals having 5.6#fasting glucose,7.0 mmol/l. Homeostasis
model assessment of insulin resistance (HOMA-IR) and beta-cell
function (HOMA-B) was estimated by Levy’s computer model
[11]. Written informed consents were obtained from all partici-
pants, and study protocol was approved by the Institutional
Review Board of the Institute for Nutritional Sciences.
Genotyping
Genomic DNA was extracted from peripheral blood mononu-
clear cell (PBMCs) by salting-out procedure (http://protocol-
online.org/prot/Detailed/3171.html). A total of nine single
nucleotide polymorphisms (SNP) with a minor allele frequency
(MAF) larger than 0.05 in HapMap CHB (in or near gene MADD,
ADRA2A, CRY2, GLIS3, PROX1, FADS1, C2CD4B, IGF1, IRS1)
were selected from the recent GWAS studies of type 2 diabetes or
fasting glucose [2,6]. Variants in or near ADCY5, SLC2A2 were not
genotyped because of low MAF (,5%) in HapMap CHB
database. All variants were genotyped using GenomeLab
SNPstream Genotyping System (Beckman Coulter) or ABI
PRISM 7900HT sequence detection system (Applied Biosystems).
The overall genotyping success rates were .98.8%, and the
concordance rates were .98.7% in 12% of total sample (Table
S1). The genotype distribution of all polymorphisms were in
Hardy-Weinberg equilibrium (P.0.05 in whole individuals and
each regional subpopulation) (Table S1).
Statistical analyses
Hardy-Weinberg equilibrium was examined by likelihood ratio
Chi-square tests. Generalized linear regression analyses were
applied to test the associations of each SNP with quantitative traits.
The data of HOMA-IR was natural log-transformed before
analyses because of skewed distribution. Participants with known
diabetes or receiving glucose-lowering treatment (N=276) were
excluded from the analyses with quantitative traits. Logistic
regression was used to test the associations of each SNP with risk
of diabetes and/or IFG, using individuals with NFG as reference
(control) group. Glucose-increasing alleles were determined based
upon the recent GWAS results [2,6]. A recessive and dominant
model was used for the SNP with glucose-increasing allele
frequencies .90% (rs10885122 and rs7944585) and ,10%
(rs2943641), respectively, and an additive model was used for those
withglucose-increasing allele frequencies ranging from 10% to 90%
(rs7034200, rs11605924, rs35767, rs11071657, rs340874 and
rs174550). All association analyses were performed separately in
Beijingand Shanghaisubpopulationsand theninpooled population
with adjustment firstly for sex, age, region (only for analyses in
pooled population) and BMI (where appropriate) and secondly for
other confounding factors including family history of diabetes,
HDL, LDL, log-transformed triglyceride, lipid lowering medica-
tion, hypertension, anti-hypertensive medication. We conducted
meta-analyses applying Cochran Q test in Stata to evaluate the
combined effect sizes of subpopulations and the heterogeneity of
effect sizes between subpopulations (Beijing vs. Shanghai).
We hypothesized that the associations between genotypes and
type 2 diabetes risks were mediated by HOMA-B or HOMA-IR.
The expected effect of the genotypes on the type 2 diabetes risk was
therefore calculated be multiplying the magnitudes of the association
between the genotypes and HOMA-B/HOMA-IR and of associa-
tion between HOMA-B/HOMA-IR and type 2 diabetes risk [12].
The statisticalsignificancebetween expected andobserved effectwas
assessed using t-test. We estimated the proportion of the possible
mediation of the type 2 diabetes associations by HOMA-B or
HOMA-IR through dividing the expected effect by the observed
effect. We also assessed the discriminatory ability of genetic variants
for type 2 diabetes risk and/or IFG by calculating the area under
Receiver Operating Characteristics (ROC) curve (AUC). Power
calculations were performed using effect size and odd ratios reported
in the original GWAS [2,6] and sample size and glucose-increasing
allele frequencies of our study with Quanto software (http://hydra.
usc.edu/gxe). Statistical analyses were conducted using Stata
(version 9.2; Stata, College Station, TX) or SAS (version 9.2; SAS
Institute, Inc.). Two-side P values ,0.05 were considered to be
statistically significant.
Results
Descriptive characteristics of the population are shown in
Table 1. The prevalence of type 2 diabetes was high in Beijing
subpopulation (17.3%) compared to Shanghai subpopulation
(9.3%). Accordingly, the levels of diabetes related quantitive traits,
including BMI, fasting glucose, HbA1C and HOMA-B, were
significantly different between two subpopulations.
Of the nine variants genotyped in this study, GLIS3-rs7034200
showed significant associations with fasting glucose
(b=0.07 mmol/l, P=0.03) and HOMA-B (b=23.03%,
P=0.009), but not with BMI, HbA1c or HOMA-IR (P$0.20)
(Table 2). None of the remaining eight loci (MADD-rs7944584,
ADRA2A-rs10885122, CRY2-rs11605924, PROX1-rs340874,
C2CD4B-rs11071657, IGF1-rs35767, IRS1- rs2943641 and
FADS1-rs174550) were associated with any of glycemic traits
(P$0.10), while a nominal association was observed between
PROX1-rs340874 and BMI (P=0.04). Most of the associations
with these quantitative traits were similar between Shanghai and
Beijing subpopulations, except for the associations with BMI for
ADRA2A-rs10885122 and FADS1-rs174550 (P for heterogeneity
=0.005 and 0.08, respectively), and with HOMA-IR for IRS1-
rs2943641 (P for heterogeneity =0.02) (Table S2).
Of the nine SNPs, GLIS3-rs7034200 was also significantly
associated with type 2 diabetes (OR [95%CI] =1.27 [1.09–1.49],
P=0.003), IFG (OR [95%CI] =1.21 [1.07–1.36], P=0.002), and
combined IFG/type 2 diabetes (OR [95%CI] =1.23 [1.10–1.37],
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rs11605924 was significantly associated with increased risk of
combined IFG/type 2 diabetes (OR [95%CI] = 1.15[1.01–1.30],
P=0.04). Although the associations with type 2 diabetes (OR
[95%CI] =1.14[0.94–1.37])andIFG(OR[95%CI] =1.15 [1.00–
1.33]) showed similar trends, the results did not reach nominal
significance (P$0.05). The direction of associations for loci
ADRA2A, IGF1 and IRS1 were consistent to those observed in the
previous GWAS [2,6], however none of the remaining loci were
associated with type 2 diabetes (P$0.21), IFG (P$0.10) or
combined IFG/type 2 diabetes (P$0.22). Power calculation
suggested that our study had less than 25% power to detect the
previously reported OR and beta values in white Europeans [2,6] at
P,0.05. Notably, further adjustment for family history of diabetes,
lipid profile, medication information and hypertension did not
materially change the associations of GLIS3-rs7034200 with
HOMA-B and type 2 diabetes, but abolished the association
between CRY2 and combined IFG/type 2 diabetes (Table S3).
The ROCAUC values of GLIS3-rs7034200 and CRY2-rs11605924
for the discrimination of type 2 diabetes were 0.543 and 0.511
respectively. While the combination of all nine SNPs significantly
(P=0.01) improved ROCAUC (ROCAUC=0.574), the discrimina-
tive accuracy of type 2 diabetes risk remains low (Table S4).
To examine whether impaired beta-cell function (HOMA-B) or
insulin resistance (HOMA-IR) mediates the associations of GLIS3-
rs7034200 with type 2 diabetes and/or combined IFG/type 2
diabetes, we re-evaluated the associations in multivariate model
(adjusting for family history of diabetes, lipid profile, medication
information, hypertension and life-style factors) with further
adjustment for HOAM-B or HOMA-IR. However, the associations
with type 2 diabetes and/or combined IFG/type 2 diabetes were
abolished or attenuated; i.e. OR for type 2 diabetes: 1.19 [0.96–
1.49]), P=0.11; and OR for IFG/type 2 diabetes: 1.15 [1.01–1.31],
P=0.04) after adjusting for HOMA-B, whereas the associations
remained unchanged after further adjustment for HOMA-IR (Table
S5). We then performed Mendelian randomization analysis to test
whether and to what extent the diabetes association might be
attributable to impaired beta-cell function (HOMA-B). We found
that the expected effect (b=0.15), estimated by multiplying the
magnitudeoftheassociationbetween GLIS3-rs7034200 and HOMA-
B and of the association between HOMA-B and type 2 diabetes risk,
was comparable to the observed effect (b=0.24, P(exp/obs)=0.53).
HOMA-B explained 63% of the association between GLIS3-
rs7034200 and type 2 diabetes, calculated by comparing the expected
effect with the observed effect (Table 4).
Table 1. Characteristics of the study population.
Beijing Shanghai P value
n (%male) 1574 (45.2) 1636 (43.5) 0.41
Age (years) 58.365.9 58.966.0 0.01
BMI (kg/m
2) 25.263.7 23.763.3 ,0.0001
Fasting glucose (mmol/l) 6.1661.96 5.5361.42 ,0.0001
HbA1C (%) 6.08 6 1.22 5.90 6 0.96 ,0.0001
HOMA-B 100.1644.9 120.0646.9 ,0.0001
HOMA-IR 1.8261.56 1.7460.86 0.67
Diabetes (%) 272 (17.3) 152 (9.3) ,0.0001
IFG (%) 579 (36.7) 293 (18.3) ,0.0001
Data are presented as mean 6 SD, or n (%), unless otherwise indicated.
P values represent significance of the differences between individuals from
Beijing and Shanghai.
doi:10.1371/journal.pone.0021464.t001
Table 2. Associations with type 2 diabetes-related quantitative traits.
SNP Gene
Alleles
(glucose-
increasing*/
other)
Freq.
glucose-
increasing
allele* Glucose HbA1c HOMA-B HOMA-IR BMI
b(SE) P
{ b(SE) P
{ b(SE) P
{ b(SE) P
{ b(SE) P
{
rs7944584 MADD A/T 0.97 0.11 (0.10) 0.24 0.07 (0.06) 0.25 23.99 (3.54) 0.26 20.008 (0.039) 0.84 20.10 (0.28) 0.71
rs10885122 ADRA2A G/T 0.92 0.04 (0.06) 0.50 0.05 (0.04) 0.26 1.38 (2.23) 0.54 0.019 (0.024) 0.45 20.13 (0.17) 0.45
rs11605924 CRY2 A/C 0.77 0.03 (0.04) 0.43 20.002
(0.03)
0.93 21.70 (1.37) 0.22 0.003 (0.015) 0.84 20.09 (0.11) 0.42
rs7034200 GLIS3 A/C 0.43 0.07 (0.03) 0.03 0.01 (0.02) 0.53 23.03 (1.15) 0.00920.005 (0.013) 0.67 0.12 (0.09) 0.20
rs340874 PROX1 C/T 0.38 20.04 (0.03) 0.18 20.02 (0.02) 0.28 1.95 (1.19) 0.10 0.015 (0.013) 0.25 20.19 (0.09) 0.04
rs11071657 C2CD4B A/G 0.63 0.007 (0.03) 0.84 0.03 (0.02) 0.19 0.43 (1.21) 0.72 0.002 (0.013) 0.89 0.04 (0.09) 0.65
rs35767 IGF1 G/A 0.66 0.02 (0.03) 0.63 0.01 (0.02) 0.53 20.13 (1.22) 0.92 0.008 (0.013) 0.57 20.14 (0.10) 0.14
rs2943641 IRS1 T/C 0.07 0.01 (0.07) 0.82 20.002
(0.04)
0.96 0.65 (2.39) 0.78 20.006 (0.026) 0.83 20.03 (0.19) 0.89
rs174550 FADS1 T/C 0.65 0.04 (0.03) 0.27 0.02 (0.02) 0.37 20.56 (1.21) 0.65 0.007 (0.013) 0.61 0.16 (0.10) 0.09
Data are presented as b 6 SE unless otherwise indicated. HOMA-IR was log-transformed before analyses.
Participants previously diagnosed with type 2 diabetes or receiving glucose-lowering treatment (n=264) were excluded from the analyses for diabetes related traits.
A recessive and dominant model was used for the SNP with glucose-increasing allele frequencies .90% (rs10885122 and rs7944585) and ,10% (rs2943641),
respectively, and an additive model was used for those with glucose-increasing allele frequencies ranging from 10% to 90% (rs7034200, rs11605924, rs35767,
rs11071657, rs340874 and rs174550).
P values ,0.05 were shown in bold.
*Glucose-increasing alleles were determined based upon the recent GWAS results [2,6].
{P values were adjusted for age, sex, BMI and region.
{P values were adjusted for age, sex and region.
doi:10.1371/journal.pone.0021464.t002
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In this population-based cohort of Chinese Hans, we confirmed
the associations of GLIS3-rs7034200 with fasting glucose and beta-
cell function as estimated by HOMA-B, as well as with risk of type
2 diabetes and/or IFG. Further analyses suggested that association
between GLIS3-rs7034200 and type 2 diabetes was mediated by
HOMA-B. We also observed a moderate association between
CRY2-rs11605924 and combined IFG/type 2 diabetes. Although
the associations between the SNPs in MADD, ADRA2A, C2CD4B,
IGF1, IRS1and FADS1 with fasting glucose or type 2 diabetes were
directionally consistent with those observed for white Europeans
and of similar magnitude to that observed in the previous GWAS,
none reached nominal significance [6].
In whites of European ancestry, GLIS3 was identified as in GWA
studies for fasting glucose and beta-cell function as estimated by
HOMA-B, yet the locus was also nominally associated with type 2
diabetes [6]. In the present study of Chinese Hans, GLIS3-rs7034200
was significantly associated not only with fasting glucose and HOMA-
B, but also with type 2 diabetes risk. Consistent with our results, a
recent study in case-control samples of Chinese Hans also observed a
significant association between GLIS3-rs7034200 and type 2 diabetes
[8]. Interestingly, the observed OR for type 2 diabetes risk in this study
was significantly larger than those reported previously for white
Europeans [6] (1.27 vs. 1.03, P=0.009). Since GLIS3-rs7034200 is
more likely a marker of the causal variant and the risk A-allele
frequency of GLIS3-rs7034200 is similar between Chinese Hans and
white Europeans, the disparity in the magnitude of the associations
with glucose and type 2 diabetes might be due to ethnic-specific LD
pattern between GLIS3-rs7034200 and the as-yet unidentified causal
variant. Nevertheless, we cannot rule out the possibility that the
observed effect size might be population-specific or overestimated due
to the ‘‘winner’s curse’’. Recently, a large study in middle-aged Danish
population reported that GLIS3-rs7034200 was associated with
glucose-stimulated insulin response, and 57% of its effect on fasting
glucose could be ascribed to association with insulin release (BIGTT-
AIR) [7]. Consistent with their observation, we found that impaired
beta-cell function estimated by HOMA-B explained about 63% of the
association between GLIS3-rs7034200 and type 2 diabetes, and further
adjustment for HOMA-B abolished this association. These findings are
also consistent with the evidence from in vivo and in vitro studies that
suggest for a critical role of Glis3 in the regulation of pancreatic beta-
cell development and insulin gene expression [13]. Since HOMA-B
explained only 63% of the association between GLIS3-rs7034200 and
type 2 diabetes, additional unknown mechanisms independent of
insulin release might also mediate the association.
For CRY2-rs11605924 variant, we observed a moderate association
with combined IFG/type 2 diabetes, but not with type 2 diabetes risk
or its related traits. Since the association of CRY2-rs11605924 with
combined IFG/type 2 diabetes was abolished after further adjustment
for other confounding factors including family history of diabetes, lipid
profile, medication information and hypertension, this result should be
interpreted with caution. We also failed to replicate the associations of
other seven SNPs with fasting glucose and other diabetes-related traits.
For these loci (ADRA2A, CRY2, MADD, IGF1and FADS1), the
associations with fasting glucose were directionally consistent with
those previously reported by the original study with comparable effect
sizes [6]. A possible reason for our failure to completely confirm
formerly identified associations of these variants is that genetic variants
might exhibit their effects in the setting of a specific environment; hence
the inconsistence might be induced by the population difference in
environment factors. Certainly, given that we have less than 25%
power to detect the previously reported beta values for fasting glucose
or ORs for type 2 diabetes at P,0.05 (Table S1), we can not rule out
the possibility that it might be due to insufficient power of our study.
Differences in allele frequencies and LD patterns between Chinese
Hans and Europeans are also possible reasons. The beta values for the
associations between PROX1-rs340874 and fasting glucose and
between IRS1-rs2943641 and HOMA-IR were in the opposite
direction to those reposted in previous GWAS [2,6], but these
associations were not significant. Studies with larger sample size are
needed to draw a more definite conclusion. Notably, we observed a
significant difference in genotype distribution of FADS1-rs174550
between Shanghai and Beijing subpopulations. Consistent with our
Table 3. Associations with type 2 diabetes and combined IFG/type 2 diabetes
SNP Gene
Alleles
(glucose
increasing*/
other)
T2DM/IFG/
NFG
Freq. glucose-
increasing
allele* (T2DM/
IFG/NFG) T2DM vs. NFG IFG vs. NFG
Combined IFG/T2DM
vs. NFG
OR(95%CI) P OR(95%CI) P OR(95%CI) P
rs7944584 MADD A/T 424/8771902 0.96/0.98/0.97 1.00 (0.63–1.58) 0.99 1.39 (0.94–2.05) 0.10 1.23 (0.88–1.71) 0.22
rs10885122 ADRA2A G/T 423/878/1893 0.93/0.91/0.92 1.23 (0.89–1.79) 0.21 0.86 (0.69–1.08) 0.20 0.96 (0.78–1.18) 0.70
rs11605924 CRY2 A/C 423/872/1884 0.78/0.78/0.77 1.14 (0.94–1.37) 0.18 1.15 (1.00–1.33) 0.05 1.15 (1.01–1.30) 0.04
rs7034200 GLIS3 A/C 422/870/1881 0.47/0.46/0.41 1.27 (1.09–1.49) 0.003
{ 1.21 (1.07–1.36) 0.002
{ 1.23 (1.10–1.37) 0.0002
{
rs340874 PROX1 C/T 423/869/1887 0.35/0.38/0.38 0.91 (0.77–1.07) 0.26 1.02 (0.90–1.15) 0.76 0.98 (0.88–1.09) 0.68
rs11071657 C2CD4B A/G 422/877/1889 0.62/0.62/0.63 0.94 (0.80–1.10) 0.43 0.96 (0.85–1.08) 0.48 0.95 (0.85–1.06) 0.39
rs35767 IGF1 G/A 424/875/1899 0.67/0.66/0.66 1.07 (0.91–1.26) 0.44 1.03 (0.91–1.16) 0.67 1.04 (0.93–1.16) 0.49
rs2943641 IRS1 T/C 422/873/1895 0.08/0.06/0.07 1.16 (0.85–1.57) 0.35 0.92 (0.71–1.18) 0.49 1.01 (0.81–1.26) 0.93
rs174550 FADS1 T/C 419/873/1886 0.67/0.68/0.63 0.99 (0.84–1.16) 0.90 1.04 (0.92–1.18) 0.53 1.03 (0.92–1.15) 0.66
Data are presented as OR (95%CI) unless otherwise indicated. P values were adjusted for age, sex, BMI and region.
A recessive and dominant model was used for the SNP with glucose-increasing allele frequencies .90% (rs10885122 and rs7944585) and ,10% (rs2943641),
respectively, and an additive model was used for those with glucose-increasing allele frequencies ranging from 10% to 90% (rs7034200, rs11605924, rs35767,
rs11071657, rs340874 and rs174550).
P values ,0.05 were shown in bold.
*Glucose-increasing alleles were determined based upon the recent GWAS results [2,6]
{The associations remained significant after Bonferroni correction for multiple tests, and the Bonferroni corrected cutoff P value is 0.006 (0.05/9 tests).
doi:10.1371/journal.pone.0021464.t003
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rs174550 (,25 kb) showed significant difference in allele frequencies
between the northern and southern Hans cluster [14]. Therefore, it is
possible that the genetic architecture of FADS1 gene might be different
between the Northern and Southern Chinese Hans. Additionally, the
associations of MADD, ADRA2A, IRS1 and FASD1 with type 2 diabetes
or its related traits were directional different between two subpopu-
lations. The discrepancies might be partially explained by the
geographic differences in diabetes prevalence which may due to
sampling, although further studies are clearly needed to clarify this.
In conclusion, our results confirmed the associations of GLIS3-
rs7034200 with fasting glucoseand risk of type 2 diabetes, and we also
observed a moderate significant association between CRY2-
rs11605924 and combined IFG/type 2 diabetes in Chinese Hans.
The GLIS3-rs7034200 exhibited larger effect size on type 2 diabetes
compared to that in white Europeans, and its contribution to type 2
diabetes risk is mainly mediated through impaired beta-cell function.
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